Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti-PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Purpose

Most patients with locally advanced or metastatic tumors succumb to their disease. Thus, there is a substantial need for novel therapeutic strategies to improve the outcome for patients with advanced or metastatic melanoma. Targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition as well as targeting immunologic checkpoint control with an antiPD-L1 antibody have emerged as treatment option.

In this study the best timing for sequential use of both treatment options (BRAF/MEK inhibition and antiPD-L1 antibody) in patients with unresectable or metastatic BRAFV600 mutant melanoma will be assessed.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant Melanoma</td>
<td>Drug: Vemurafenib Drug: Cobimetinib Drug: Atezolizumab</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

Study Type: Interventional  
Study Design:  
Allocation: Randomized  
Endpoint Classification: Safety/Efficacy Study  
Intervention Model: Parallel Assignment  
Masking: Open Label  
Primary Purpose: Treatment

Official Title: A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti-PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Resource links provided by NLM:

MedlinePlus related topics: Melanoma

Drug Information available for: Vemurafenib Cobimetinib Atezolizumab

Genetic and Rare Diseases Information Center resources: Carcinoid Tumor Neuroepitheloma

U.S. FDA Resources

Further study details as provided by University Hospital, Essen:

Primary Outcome Measures:

- Time to Second Objective Disease Progression [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Time to Second Objective Disease Progression (PFS2) defined as time from start of run-in phase (date of first intake of study drug) to second objective disease progression according to RECIST v. 1.1. (PD2) following randomization or death from any cause
Secondary Outcome Measures:

- Adverse events according to CTCAE Version 4.0 criteria (Safety / Toxicity) [Time Frame: Until 90 days of discontinuation of dosing of the investigational product] [Designated as safety issue: Yes]
  
  All adverse events according to CTCAE Version 4.0 criteria, that are related to the administration of the investigational agents will be assessed

- Overall survival [Time Frame: 4 years] [Designated as safety issue: No]
  
  Overall Survival (OS) of a patient defined as the time from start of run-in phase (date of first intake of study drug) until documented date of death

- Overall survival 12 months [Time Frame: 1 year] [Designated as safety issue: No]
  
  Overall survival rate at 12 months defined as the rate of patients alive 12 months after start of run-in phase (date of first intake of study drug)

- Overall survival 24 months [Time Frame: 2 years] [Designated as safety issue: No]
  
  Overall survival rate at 24 months defined as the rate of patients alive 24 months after start of run-in phase (date of first intake of study drug)

- 12-months disease control rate (DCR) [Time Frame: 1 year] [Designated as safety issue: No]
  
  DCR is defined as the rate of patients showing complete response (CR) or partial response (PR) or stable disease (SD) at 12 months after start of run-in phase (date of first intake of study drug).

- 24-months disease control rate (DCR) [Time Frame: 2 years] [Designated as safety issue: No]
  
  DCR is defined as the rate of patients showing complete response (CR) or partial response (PR) or stable disease (SD) at 24 months after start of run-in phase (date of first intake of study drug).

- Rate of patients with progressive disease who could not cross-over to subsequent line of therapy due to deterioration of ECOG status and/or brain metastases [Time Frame: 4 years] [Designated as safety issue: Yes]
  
  - From run-in phase (vemurafenib + cobimetinib) to study treatment in Arm A or Arm B
  - From vemurafenib + cobimetinib to atezolizumab (Arm A)
  - From atezolizumab to vemurafenib + cobimetinib (Arm B)

Estimated Enrollment: 176
Study Start Date: November 2016
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
</table>
| Experimental: Arm A | Drug: Vemurafenib  
|                   | 960 mg vemurafenib BID until progression or unacceptable toxicity develops |
|                   | Drug: Cobimetinib  
|                   | 60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops |
|                   | Drug: Atezolizumab  
|                   | 1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops |
|                   | Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle. |
|                   | After progression of disease patients in Arm A will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7). |
| Experimental: Arm B | Drug: Vemurafenib  
|                   | 960 mg vemurafenib BID until progression or unacceptable toxicity develops |
|                   | Drug: Cobimetinib  
|                   | 60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops |
|                   | Drug: Atezolizumab  
|                   | 1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops |
|                   | Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7). |
|                   | After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized. |
|                   | After progression of disease patients in Arm B will subsequently receive atezolizumab treatment (1200 mg/ q3w). |
At this time there is no experience concerning the sequencing strategy when using the two effective therapeutical approaches as targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition or targeting immunologic checkpoint control with an anti-PD-L1 antibody.

This is a prospective, open, multicenter, randomized phase II study in patients with unresectable or metastatic BRAFV600 mutant melanoma. In this study the scheduling of the treatment with a combined BRAF/MEK inhibition and the treatment with an anti-PD-L1 antibody will be assessed.

After a 3 months run-in period with vemurafenib and cobimetinib, all patients who did not show disease progression or treatment interruption for more than 28 days during run-in phase will be randomized in a 1:1 ratio:

- either to proceed vemurafenib and cobimetinib until disease progression and subsequently cross-over to atezolizumab treatment until disease progression (Arm A).
- or to receive the anti-PD-L1 antibody atezolizumab until disease progression and subsequently cross-back to vemurafenib and cobimetinib until disease progression (Arm B).

In a translational research program tumor tissue, blood plasma and peripheral blood mononuclear cell will be analyzed to evaluate the biologic effects of treatment sequence on the molecular profile and biomarker expression in tissue and plasma.

Eligibility

Ages Eligible for Study: 18 Years and older (Adult, Senior)

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Be willing and able to provide written informed consent for the trial.
- Male or female patient being ≥ 18 years of age on day of signing informed consent.
- Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases; all known CNS lesions must have been treated with stereotactic therapy or surgery at least 4 weeks prior to the first dose of trial treatment AND the patient must be without evidence of clinical or radiographic disease progression in the CNS for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms must have returned to baseline, the patient must have no evidence of new or enlarging brain metastases, and the patient must not have used steroids for at least 3 weeks prior to trial treatment.
- No previous therapy for the advanced or metastatic stage. Prior adjuvant therapy is permitted (e.g. Interferon, Interleukin-2-therapy, chemo- or radiotherapy). Prior adjuvant therapy has to be terminated (last dose) at least 28 days before enrolment. Patients who are in follow-up period of a clinical trial in adjuvant setting and progressing may be enrolled / randomized.
- Measurable disease, i.e., present with at least one measurable lesion per RECIST, version 1.1, for the definition of a measurable lesion.
- Presence of BRAF mutation (V600) in tumor tissue.
- Performance status of 0 or 1 on the ECOG Performance Scale.
- Adequate organ function.
- Adequate cardiac function.
- Able to take oral medications.
- Female subject of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication.
- Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to CTFG during the course of this study and for at least 6 months after completion of study therapy.

Exclusion Criteria:

- Use of any investigational or non-registered product within the 30 days before registration.
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1.
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor
- Prior major surgery.
- Known additional malignancy that is progressing or requires active treatment within 5 years prior to the study.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- History of leptomeningeal metastases.
- History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to RVO or CSR.
- History of retinal degenerative disease.
- History of allogenic bone marrow transplantation or organ transplantation.
- History of Gilbert's syndrome.
- Impaired cardiovascular function or clinically significant cardiovascular diseases.
- Uncontrolled arterial hypertension despite medical treatment.
- Impairment of gastrointestinal function or gastrointestinal disease.
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Active infection requiring systemic therapy.
• Positive test for Human Immunodeficiency Virus (HIV).
• Positive test for Hepatitis B or Hepatitis C.
• Known hypersensitivity reaction to any of the components of study treatment.
• Medical, psychiatric, cognitive or other conditions, including known alcohol or drug abuse.
• Patients having received a live, attenuated vaccine within 4 weeks prior to the first dose of trial treatment.
• Legal incapacity or limited legal capacity.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02902029

Contacts

Contact: Dirk Schadendorf, Prof. Dr.  dirk.schadendorf@uk-essen.de

Locations

Germany

SLK-Kliniken Heilbronn GmbH
Heilbronn, Baden-Wuerttemberg, Germany, 74078
Contact: Uwe Martens, Prof. Dr.  uwe.martens@slk-kliniken.de
Principal Investigator: Uwe Martens, Prof. Dr.
Sub-Investigator: Jamil Akkad

University Hospital Mannheim, Clinic for Dermatology
Mannheim, Baden-Wuerttemberg, Germany, 68167
Contact: Jochen Utikal, Prof. Dr.  jochen.utikal@umm.de
Principal Investigator: Jochen Utikal, Prof. Dr.
Sub-Investigator: Christoffer Gebhardt, Dr. med.

National Centre for Tumour Diseases (NCT)
Heidelberg, BW, Germany, 69120
Contact: Jessica Hassel, Dr. med.  jessica.hassel@med.uni-heidelberg.de
Principal Investigator: Jessica Hassel, Dr. med.
Sub-Investigator: Martin Hartmann, Dr. med

University Hospital Essen, Department of Dermatology, Skin Cancer Center
Essen, North Rhine-Westphalia, Germany, 45122
Contact: Dirk Schadendorf, Prof. Dr.  dirk.schadendorf@uk-essen.de
Principal Investigator: Dirk Schadendorf, Prof. Dr.
Sub-Investigator: Bastian Schilling, PD Dr.

HELIOS Klinikum Erfurt
Erfurt, Thuringia, Germany, 99089
Contact: Rudolf Herbst, Prof. Dr.  rudolf.herbst@helios-kliniken.de
Principal Investigator: Rudolf Herbst, Prof. Dr.
Sub-Investigator: Iwonne Kellner, Dr. med.

Medizinische Hochschule Hannover
Hannover, Germany, 30625
Contact: Ralf Gutzmer, Prof. Dr.  gutzmer.raif@mh-hannover.de
Principal Investigator: Ralf Gutzmer, Prof. Dr.
Sub-Investigator: Imke Satzger, Pd Dr.

Sponsors and Collaborators

University Hospital, Essen

Investigators

Principal Investigator: Dirk Schadendorf, Prof. Dr.  University Hospital, Essen

More Information

Responsible Party: Prof. Dr. med. Dirk Schadendorf, Prof. Dr. med., University Hospital, Essen
ClinicalTrials.gov Identifier: NCT02902029
Other Study ID Numbers: ImmunoCobiVem_2015
Study First Received: September 12, 2016
Last Updated: December 21, 2016

https://clinicaltrials.gov/ct2/show/NCT02902029?term=NCT02902029&rank=1

03.01.2017
<table>
<thead>
<tr>
<th>Health Authority:</th>
<th>Germany: Paul-Ehrlich-Institut</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Participant Data</td>
<td>No</td>
</tr>
<tr>
<td>Keywords provided by University Hospital, Essen:</td>
<td>unresectable stage IIIB, IIIC, IV melanoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional relevant MeSH terms:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
</tr>
<tr>
<td>Neuroendocrine Tumors</td>
</tr>
<tr>
<td>Neuroectodermal Tumors</td>
</tr>
<tr>
<td>Neoplasms, Germ Cell and Embryonal</td>
</tr>
<tr>
<td>Neoplasms by Histologic Type</td>
</tr>
<tr>
<td>Neoplasms</td>
</tr>
</tbody>
</table>

ClinicalTrials.gov processed this record on December 30, 2016

https://clinicaltrials.gov/ct2/show/NCT02902029?term=NCT02902029&rank=1 03.01.2017